| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lupus Erythematosus, Systemic | 218 | 2022 | 992 | 22.750 |
Why?
|
| Immunosuppressive Agents | 20 | 2022 | 149 | 3.840 |
Why?
|
| Severity of Illness Index | 58 | 2022 | 461 | 3.530 |
Why?
|
| Antibodies, Monoclonal | 23 | 2022 | 333 | 3.530 |
Why?
|
| Antiphospholipid Syndrome | 26 | 2019 | 30 | 3.510 |
Why?
|
| Lupus Nephritis | 26 | 2022 | 102 | 2.900 |
Why?
|
| Recombinant Fusion Proteins | 7 | 2021 | 233 | 2.720 |
Why?
|
| Antibodies, Monoclonal, Humanized | 27 | 2022 | 147 | 2.600 |
Why?
|
| B-Cell Activating Factor | 14 | 2022 | 32 | 2.580 |
Why?
|
| Humans | 264 | 2022 | 28581 | 2.550 |
Why?
|
| Adult | 133 | 2022 | 7922 | 2.370 |
Why?
|
| Genetic Predisposition to Disease | 49 | 2018 | 671 | 2.290 |
Why?
|
| Female | 168 | 2022 | 15471 | 2.060 |
Why?
|
| Antibodies, Antiphospholipid | 18 | 2021 | 27 | 2.050 |
Why?
|
| Male | 139 | 2022 | 13771 | 1.940 |
Why?
|
| Quality of Life | 19 | 2021 | 504 | 1.890 |
Why?
|
| Middle Aged | 97 | 2022 | 7310 | 1.860 |
Why?
|
| Polymorphism, Single Nucleotide | 48 | 2018 | 550 | 1.830 |
Why?
|
| Double-Blind Method | 31 | 2022 | 421 | 1.820 |
Why?
|
| Biomarkers | 31 | 2022 | 770 | 1.650 |
Why?
|
| Autoantibodies | 32 | 2022 | 479 | 1.650 |
Why?
|
| Treatment Outcome | 46 | 2022 | 2402 | 1.550 |
Why?
|
| Antirheumatic Agents | 10 | 2021 | 57 | 1.520 |
Why?
|
| Disease Progression | 23 | 2020 | 475 | 1.500 |
Why?
|
| Antibodies, Antinuclear | 21 | 2022 | 183 | 1.450 |
Why?
|
| Pregnancy Complications | 12 | 2020 | 111 | 1.320 |
Why?
|
| Clinical Trials as Topic | 13 | 2020 | 216 | 1.300 |
Why?
|
| Thrombosis | 11 | 2020 | 150 | 1.300 |
Why?
|
| Immunologic Factors | 4 | 2018 | 50 | 1.250 |
Why?
|
| Tumor Necrosis Factor Ligand Superfamily Member 13 | 2 | 2020 | 6 | 1.240 |
Why?
|
| Young Adult | 49 | 2022 | 2804 | 1.160 |
Why?
|
| Risk Factors | 43 | 2021 | 2111 | 1.140 |
Why?
|
| African Americans | 24 | 2020 | 352 | 1.120 |
Why?
|
| Glucocorticoids | 14 | 2022 | 115 | 1.120 |
Why?
|
| Adaptor Proteins, Signal Transducing | 6 | 2022 | 163 | 1.100 |
Why?
|
| Arthritis, Rheumatoid | 8 | 2017 | 134 | 1.070 |
Why?
|
| Glycoproteins | 10 | 2004 | 123 | 0.880 |
Why?
|
| United States Food and Drug Administration | 3 | 2011 | 45 | 0.870 |
Why?
|
| Lupus Vasculitis, Central Nervous System | 7 | 2020 | 12 | 0.850 |
Why?
|
| Dose-Response Relationship, Drug | 17 | 2022 | 611 | 0.850 |
Why?
|
| Kidney | 6 | 2017 | 286 | 0.820 |
Why?
|
| Haplotypes | 30 | 2018 | 284 | 0.800 |
Why?
|
| Lupus Erythematosus, Cutaneous | 2 | 2020 | 15 | 0.770 |
Why?
|
| Patient Reported Outcome Measures | 3 | 2020 | 66 | 0.760 |
Why?
|
| Phthalimides | 1 | 2022 | 1 | 0.750 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 4 | 2018 | 42 | 0.750 |
Why?
|
| Oligonucleotides | 3 | 2009 | 27 | 0.750 |
Why?
|
| Steroids | 3 | 2019 | 58 | 0.750 |
Why?
|
| Immunoconjugates | 2 | 2014 | 21 | 0.740 |
Why?
|
| Morpholines | 1 | 2022 | 28 | 0.740 |
Why?
|
| Drug Therapy, Combination | 14 | 2019 | 208 | 0.740 |
Why?
|
| Cohort Studies | 29 | 2021 | 893 | 0.730 |
Why?
|
| Piperidones | 1 | 2022 | 32 | 0.720 |
Why?
|
| Kidney Failure, Chronic | 3 | 2016 | 70 | 0.710 |
Why?
|
| Pharmaceutical Preparations | 1 | 2021 | 48 | 0.690 |
Why?
|
| Transmembrane Activator and CAML Interactor Protein | 1 | 2020 | 1 | 0.690 |
Why?
|
| Case-Control Studies | 32 | 2018 | 732 | 0.670 |
Why?
|
| Drug Approval | 3 | 2011 | 11 | 0.650 |
Why?
|
| Betacoronavirus | 1 | 2020 | 39 | 0.640 |
Why?
|
| Frailty | 4 | 2022 | 24 | 0.640 |
Why?
|
| Prospective Studies | 23 | 2021 | 1272 | 0.630 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 49 | 0.620 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 53 | 0.620 |
Why?
|
| Azetidines | 1 | 2019 | 6 | 0.610 |
Why?
|
| Cytokines | 6 | 2020 | 448 | 0.600 |
Why?
|
| Interferon Type I | 6 | 2022 | 56 | 0.600 |
Why?
|
| Lupus Coagulation Inhibitor | 8 | 2019 | 11 | 0.590 |
Why?
|
| Fatigue | 1 | 2019 | 64 | 0.580 |
Why?
|
| Research Design | 3 | 2017 | 185 | 0.580 |
Why?
|
| Foundations | 1 | 2018 | 4 | 0.580 |
Why?
|
| B-Lymphocytes | 10 | 2019 | 285 | 0.580 |
Why?
|
| Sleep Wake Disorders | 1 | 2019 | 65 | 0.570 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2019 | 67 | 0.570 |
Why?
|
| beta 2-Glycoprotein I | 15 | 2021 | 26 | 0.560 |
Why?
|
| Immunotherapy | 2 | 2013 | 160 | 0.560 |
Why?
|
| Research Personnel | 1 | 2018 | 39 | 0.560 |
Why?
|
| Arteriosclerosis | 3 | 2003 | 30 | 0.560 |
Why?
|
| Inducible T-Cell Co-Stimulator Ligand | 2 | 2018 | 2 | 0.550 |
Why?
|
| Lizards | 1 | 2017 | 12 | 0.550 |
Why?
|
| Dehydroepiandrosterone | 4 | 2005 | 15 | 0.550 |
Why?
|
| Withholding Treatment | 1 | 2017 | 20 | 0.540 |
Why?
|
| Physicians | 1 | 2018 | 83 | 0.540 |
Why?
|
| Symptom Flare Up | 4 | 2021 | 7 | 0.530 |
Why?
|
| Genome-Wide Association Study | 12 | 2018 | 233 | 0.530 |
Why?
|
| Complement System Proteins | 3 | 2020 | 24 | 0.520 |
Why?
|
| Health Status | 7 | 2019 | 148 | 0.520 |
Why?
|
| Pain | 2 | 2019 | 258 | 0.520 |
Why?
|
| Alleles | 19 | 2018 | 354 | 0.520 |
Why?
|
| Protein S | 5 | 2010 | 26 | 0.520 |
Why?
|
| Membrane Proteins | 6 | 2018 | 485 | 0.510 |
Why?
|
| T-Lymphocytes | 7 | 2022 | 285 | 0.510 |
Why?
|
| Endpoint Determination | 3 | 2013 | 18 | 0.500 |
Why?
|
| Practice Guidelines as Topic | 2 | 2015 | 244 | 0.500 |
Why?
|
| Drugs, Investigational | 3 | 2005 | 5 | 0.490 |
Why?
|
| Longitudinal Studies | 12 | 2021 | 426 | 0.490 |
Why?
|
| CD40 Ligand | 3 | 2014 | 13 | 0.480 |
Why?
|
| Genotype | 23 | 2015 | 461 | 0.480 |
Why?
|
| Interferon-alpha | 3 | 2016 | 50 | 0.470 |
Why?
|
| Prognosis | 11 | 2019 | 807 | 0.470 |
Why?
|
| Heart | 1 | 2016 | 224 | 0.460 |
Why?
|
| Internationality | 8 | 2019 | 31 | 0.450 |
Why?
|
| Antibodies, Anticardiolipin | 9 | 2019 | 23 | 0.450 |
Why?
|
| CD4-Positive T-Lymphocytes | 5 | 2022 | 111 | 0.450 |
Why?
|
| Biological Factors | 1 | 2014 | 12 | 0.450 |
Why?
|
| Heart Rate | 1 | 2016 | 380 | 0.440 |
Why?
|
| Atherosclerosis | 5 | 2020 | 97 | 0.440 |
Why?
|
| Remission Induction | 5 | 2021 | 58 | 0.440 |
Why?
|
| Adolescent | 22 | 2019 | 3165 | 0.440 |
Why?
|
| Reproducibility of Results | 9 | 2021 | 782 | 0.430 |
Why?
|
| DNA Methylation | 6 | 2022 | 152 | 0.430 |
Why?
|
| Mental Disorders | 3 | 2011 | 112 | 0.420 |
Why?
|
| Aged | 26 | 2020 | 5525 | 0.420 |
Why?
|
| Injections, Subcutaneous | 7 | 2018 | 60 | 0.410 |
Why?
|
| Prevalence | 11 | 2020 | 510 | 0.410 |
Why?
|
| Inducible T-Cell Co-Stimulator Protein | 1 | 2013 | 2 | 0.410 |
Why?
|
| B7-2 Antigen | 1 | 2013 | 8 | 0.410 |
Why?
|
| B7-1 Antigen | 1 | 2013 | 11 | 0.410 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 5 | 2015 | 78 | 0.410 |
Why?
|
| United States | 13 | 2018 | 2201 | 0.390 |
Why?
|
| DNA-Binding Proteins | 7 | 2014 | 490 | 0.390 |
Why?
|
| Follow-Up Studies | 12 | 2021 | 1026 | 0.380 |
Why?
|
| Clinical Trials, Phase III as Topic | 3 | 2018 | 21 | 0.380 |
Why?
|
| Rheumatology | 4 | 2021 | 18 | 0.380 |
Why?
|
| Pregnancy | 18 | 2020 | 1219 | 0.370 |
Why?
|
| Interferon Regulatory Factors | 5 | 2014 | 58 | 0.370 |
Why?
|
| Aspirin | 4 | 2018 | 125 | 0.370 |
Why?
|
| Clinical Trials, Phase II as Topic | 3 | 2017 | 25 | 0.360 |
Why?
|
| Cross-Sectional Studies | 10 | 2022 | 988 | 0.360 |
Why?
|
| Drug Administration Schedule | 6 | 2018 | 224 | 0.360 |
Why?
|
| Metabolic Syndrome | 3 | 2021 | 80 | 0.360 |
Why?
|
| Time Factors | 11 | 2020 | 1600 | 0.360 |
Why?
|
| Pregnancy Outcome | 6 | 2018 | 131 | 0.350 |
Why?
|
| Health Status Indicators | 3 | 2009 | 25 | 0.350 |
Why?
|
| Wrist Joint | 2 | 2013 | 4 | 0.350 |
Why?
|
| Headache | 4 | 2021 | 34 | 0.350 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 12 | 2019 | 257 | 0.340 |
Why?
|
| International Cooperation | 6 | 2018 | 20 | 0.340 |
Why?
|
| Surveys and Questionnaires | 5 | 2019 | 994 | 0.330 |
Why?
|
| Antigens, CD | 6 | 2015 | 140 | 0.330 |
Why?
|
| Genetic Loci | 6 | 2013 | 77 | 0.330 |
Why?
|
| Antibody Specificity | 6 | 2013 | 114 | 0.330 |
Why?
|
| Prednisone | 5 | 2021 | 53 | 0.320 |
Why?
|
| Metacarpophalangeal Joint | 1 | 2009 | 5 | 0.320 |
Why?
|
| Edema | 1 | 2009 | 18 | 0.320 |
Why?
|
| Logistic Models | 11 | 2020 | 409 | 0.320 |
Why?
|
| Immunoglobulin G | 6 | 2021 | 272 | 0.310 |
Why?
|
| Registries | 9 | 2019 | 393 | 0.310 |
Why?
|
| Placebos | 4 | 2020 | 48 | 0.310 |
Why?
|
| Incidence | 7 | 2020 | 568 | 0.310 |
Why?
|
| Lymphocyte Activation | 3 | 2020 | 210 | 0.310 |
Why?
|
| Rituximab | 4 | 2016 | 64 | 0.300 |
Why?
|
| Bone Marrow | 1 | 2009 | 81 | 0.300 |
Why?
|
| Antibodies, Bacterial | 2 | 2021 | 103 | 0.300 |
Why?
|
| Pre-Eclampsia | 3 | 2019 | 49 | 0.300 |
Why?
|
| Decision Making | 2 | 2021 | 177 | 0.300 |
Why?
|
| Immunity, Innate | 2 | 2013 | 231 | 0.290 |
Why?
|
| Transcription Factors | 4 | 2017 | 523 | 0.290 |
Why?
|
| Platelet Aggregation Inhibitors | 2 | 2018 | 191 | 0.290 |
Why?
|
| Serologic Tests | 2 | 2019 | 19 | 0.290 |
Why?
|
| Polymorphism, Genetic | 5 | 2018 | 166 | 0.290 |
Why?
|
| CD11b Antigen | 4 | 2009 | 42 | 0.290 |
Why?
|
| Adjuvants, Immunologic | 2 | 2005 | 68 | 0.290 |
Why?
|
| Vitamin D | 2 | 2021 | 51 | 0.290 |
Why?
|
| Hydroxychloroquine | 3 | 2021 | 20 | 0.280 |
Why?
|
| Patient Selection | 3 | 2022 | 149 | 0.280 |
Why?
|
| Vitamin D Deficiency | 2 | 2021 | 31 | 0.280 |
Why?
|
| Ikaros Transcription Factor | 2 | 2022 | 9 | 0.280 |
Why?
|
| Disability Evaluation | 3 | 2019 | 54 | 0.280 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2009 | 128 | 0.280 |
Why?
|
| Comorbidity | 7 | 2020 | 259 | 0.280 |
Why?
|
| Animals | 14 | 2017 | 10580 | 0.280 |
Why?
|
| Immune Tolerance | 2 | 2005 | 52 | 0.270 |
Why?
|
| RNA, Messenger | 6 | 2017 | 667 | 0.270 |
Why?
|
| src-Family Kinases | 3 | 2014 | 71 | 0.270 |
Why?
|
| Signal Transduction | 4 | 2020 | 1454 | 0.260 |
Why?
|
| Gene Expression Regulation | 7 | 2018 | 633 | 0.260 |
Why?
|
| Adrenal Cortex Hormones | 6 | 2018 | 75 | 0.260 |
Why?
|
| Linkage Disequilibrium | 12 | 2016 | 108 | 0.260 |
Why?
|
| Neutrophils | 5 | 2019 | 183 | 0.260 |
Why?
|
| Standard of Care | 3 | 2019 | 12 | 0.260 |
Why?
|
| Autoimmunity | 3 | 2016 | 158 | 0.250 |
Why?
|
| Predictive Value of Tests | 8 | 2021 | 480 | 0.250 |
Why?
|
| Lupus Erythematosus, Discoid | 3 | 2018 | 18 | 0.240 |
Why?
|
| Epigenesis, Genetic | 5 | 2022 | 148 | 0.240 |
Why?
|
| STAT4 Transcription Factor | 3 | 2018 | 23 | 0.240 |
Why?
|
| Psychotic Disorders | 2 | 2019 | 22 | 0.240 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2016 | 247 | 0.240 |
Why?
|
| Asian Americans | 5 | 2017 | 40 | 0.240 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 3 | 2022 | 50 | 0.240 |
Why?
|
| Sex Factors | 9 | 2021 | 467 | 0.240 |
Why?
|
| Blood Vessels | 2 | 2003 | 58 | 0.230 |
Why?
|
| Homeostasis | 3 | 2009 | 118 | 0.230 |
Why?
|
| Activities of Daily Living | 2 | 2019 | 106 | 0.230 |
Why?
|
| Odds Ratio | 4 | 2020 | 236 | 0.230 |
Why?
|
| Phenotype | 10 | 2015 | 682 | 0.230 |
Why?
|
| Monocytes | 5 | 2019 | 135 | 0.230 |
Why?
|
| Blood Coagulation | 4 | 2001 | 120 | 0.220 |
Why?
|
| Immunoglobulin A | 2 | 2021 | 23 | 0.220 |
Why?
|
| MicroRNAs | 2 | 2022 | 301 | 0.220 |
Why?
|
| Plasma Exchange | 2 | 2020 | 104 | 0.220 |
Why?
|
| Contraceptives, Oral, Combined | 2 | 2019 | 5 | 0.220 |
Why?
|
| Drug Design | 1 | 2004 | 63 | 0.220 |
Why?
|
| Terminology as Topic | 2 | 2017 | 61 | 0.220 |
Why?
|
| Electrocardiography | 2 | 2016 | 394 | 0.210 |
Why?
|
| Protein S Deficiency | 2 | 2001 | 5 | 0.210 |
Why?
|
| Kaplan-Meier Estimate | 4 | 2019 | 194 | 0.210 |
Why?
|
| Adaptive Immunity | 2 | 2014 | 38 | 0.210 |
Why?
|
| Receptors, Cell Surface | 3 | 2015 | 114 | 0.210 |
Why?
|
| Genetic Linkage | 3 | 2018 | 95 | 0.210 |
Why?
|
| Risk Assessment | 4 | 2019 | 622 | 0.210 |
Why?
|
| Multicenter Studies as Topic | 2 | 2002 | 47 | 0.210 |
Why?
|
| Precision Medicine | 2 | 2018 | 76 | 0.210 |
Why?
|
| Gonadal Steroid Hormones | 1 | 2003 | 24 | 0.200 |
Why?
|
| Quantitative Trait Loci | 3 | 2018 | 53 | 0.200 |
Why?
|
| Dietary Supplements | 1 | 2005 | 265 | 0.200 |
Why?
|
| Apolipoproteins | 2 | 2014 | 21 | 0.200 |
Why?
|
| Treatment Failure | 2 | 2016 | 72 | 0.200 |
Why?
|
| Aged, 80 and over | 9 | 2017 | 2045 | 0.200 |
Why?
|
| Lipoproteins, HDL | 2 | 2014 | 41 | 0.200 |
Why?
|
| Stroke | 1 | 2006 | 256 | 0.190 |
Why?
|
| STAT1 Transcription Factor | 3 | 2018 | 38 | 0.190 |
Why?
|
| Pregnancy Trimester, First | 2 | 2020 | 14 | 0.190 |
Why?
|
| Abatacept | 2 | 2014 | 5 | 0.190 |
Why?
|
| Drug Delivery Systems | 1 | 2005 | 236 | 0.190 |
Why?
|
| Peptides | 1 | 2005 | 293 | 0.190 |
Why?
|
| American Native Continental Ancestry Group | 3 | 2017 | 22 | 0.190 |
Why?
|
| Disease Management | 2 | 2013 | 90 | 0.190 |
Why?
|
| DNA | 9 | 2017 | 375 | 0.190 |
Why?
|
| Biopsy | 4 | 2016 | 207 | 0.180 |
Why?
|
| Proportional Hazards Models | 6 | 2019 | 226 | 0.180 |
Why?
|
| Chromosome Mapping | 5 | 2013 | 128 | 0.180 |
Why?
|
| Autoimmune Diseases | 3 | 2018 | 166 | 0.180 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2022 | 72 | 0.180 |
Why?
|
| Mass Screening | 2 | 2013 | 156 | 0.180 |
Why?
|
| Genetic Association Studies | 7 | 2018 | 115 | 0.180 |
Why?
|
| B-Lymphocyte Subsets | 3 | 2016 | 30 | 0.180 |
Why?
|
| Promoter Regions, Genetic | 5 | 2014 | 344 | 0.180 |
Why?
|
| Influenza Vaccines | 2 | 2011 | 51 | 0.180 |
Why?
|
| Enterococcus | 1 | 2021 | 19 | 0.180 |
Why?
|
| Anticoagulants | 3 | 2020 | 295 | 0.170 |
Why?
|
| Qualitative Research | 2 | 2020 | 200 | 0.170 |
Why?
|
| Interleukin-1 Receptor-Associated Kinases | 2 | 2012 | 14 | 0.170 |
Why?
|
| Complement C4 | 3 | 2017 | 16 | 0.170 |
Why?
|
| Methyl-CpG-Binding Protein 2 | 2 | 2012 | 16 | 0.170 |
Why?
|
| Lymphocyte Count | 2 | 2018 | 15 | 0.170 |
Why?
|
| Drug Costs | 1 | 2020 | 17 | 0.170 |
Why?
|
| Models, Theoretical | 1 | 2021 | 134 | 0.170 |
Why?
|
| Genetic Variation | 4 | 2014 | 245 | 0.170 |
Why?
|
| Patient Participation | 2 | 2020 | 56 | 0.170 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2020 | 16 | 0.170 |
Why?
|
| Disseminated Intravascular Coagulation | 1 | 2020 | 16 | 0.170 |
Why?
|
| Multivariate Analysis | 5 | 2019 | 302 | 0.170 |
Why?
|
| Protein C | 1 | 2000 | 38 | 0.160 |
Why?
|
| Fibrinogen | 1 | 2020 | 50 | 0.160 |
Why?
|
| Intestines | 1 | 2021 | 118 | 0.160 |
Why?
|
| Sex Hormone-Binding Globulin | 1 | 2000 | 4 | 0.160 |
Why?
|
| Thrombotic Microangiopathies | 1 | 2020 | 24 | 0.160 |
Why?
|
| Proteinuria | 2 | 2017 | 14 | 0.160 |
Why?
|
| Insulin Resistance | 1 | 2021 | 176 | 0.160 |
Why?
|
| Cranial Nerve Diseases | 1 | 2019 | 10 | 0.160 |
Why?
|
| Receptors, Urokinase Plasminogen Activator | 1 | 2019 | 11 | 0.160 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2019 | 18 | 0.160 |
Why?
|
| Platelet Count | 1 | 2020 | 111 | 0.160 |
Why?
|
| Postpartum Period | 1 | 2020 | 72 | 0.160 |
Why?
|
| Gene Frequency | 8 | 2013 | 185 | 0.160 |
Why?
|
| Contraceptives, Oral, Hormonal | 1 | 2019 | 9 | 0.160 |
Why?
|
| Visual Analog Scale | 1 | 2019 | 6 | 0.160 |
Why?
|
| Antiviral Agents | 1 | 2020 | 114 | 0.150 |
Why?
|
| Receptors, Complement | 1 | 1999 | 6 | 0.150 |
Why?
|
| Complement Inactivator Proteins | 1 | 1999 | 8 | 0.150 |
Why?
|
| Apolipoprotein A-I | 2 | 1998 | 38 | 0.150 |
Why?
|
| Purines | 1 | 2019 | 17 | 0.150 |
Why?
|
| Patient Acuity | 1 | 2019 | 6 | 0.150 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2021 | 135 | 0.150 |
Why?
|
| Evidence-Based Medicine | 2 | 2011 | 146 | 0.150 |
Why?
|
| Diagnosis, Differential | 4 | 2021 | 378 | 0.150 |
Why?
|
| Socioeconomic Factors | 2 | 2017 | 251 | 0.150 |
Why?
|
| Osteopontin | 1 | 2019 | 10 | 0.150 |
Why?
|
| HLA Antigens | 2 | 2017 | 61 | 0.150 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 3 | 2012 | 285 | 0.150 |
Why?
|
| Europe | 5 | 2019 | 99 | 0.150 |
Why?
|
| Injections, Intravenous | 3 | 2015 | 66 | 0.150 |
Why?
|
| Major Histocompatibility Complex | 1 | 2018 | 28 | 0.150 |
Why?
|
| Interferons | 2 | 2022 | 70 | 0.150 |
Why?
|
| Pandemics | 1 | 2020 | 196 | 0.150 |
Why?
|
| Sulfonamides | 1 | 2019 | 73 | 0.150 |
Why?
|
| Pyrazoles | 1 | 2019 | 70 | 0.150 |
Why?
|
| Sensitivity and Specificity | 4 | 2012 | 524 | 0.150 |
Why?
|
| Neoplasms | 3 | 2021 | 857 | 0.150 |
Why?
|
| Periodontitis | 1 | 2018 | 11 | 0.140 |
Why?
|
| Glomerular Filtration Rate | 2 | 2016 | 48 | 0.140 |
Why?
|
| Interleukins | 2 | 2011 | 112 | 0.140 |
Why?
|
| Randomized Controlled Trials as Topic | 4 | 2018 | 389 | 0.140 |
Why?
|
| Arthritis | 1 | 2018 | 29 | 0.140 |
Why?
|
| Cerebrovascular Disorders | 1 | 2018 | 46 | 0.140 |
Why?
|
| Ribosomal Proteins | 3 | 2016 | 20 | 0.140 |
Why?
|
| Gene Expression | 2 | 2017 | 417 | 0.140 |
Why?
|
| Nucleosomes | 1 | 2017 | 18 | 0.140 |
Why?
|
| Drug Prescriptions | 1 | 2018 | 46 | 0.140 |
Why?
|
| Complement C3 | 2 | 2015 | 21 | 0.140 |
Why?
|
| Complement Activation | 1 | 2018 | 27 | 0.140 |
Why?
|
| Nuclear Proteins | 3 | 2016 | 249 | 0.140 |
Why?
|
| San Francisco | 1 | 2017 | 12 | 0.140 |
Why?
|
| Endothelium, Vascular | 2 | 2012 | 328 | 0.140 |
Why?
|
| Central Nervous System Diseases | 2 | 2008 | 13 | 0.140 |
Why?
|
| Genetic Load | 1 | 2017 | 6 | 0.140 |
Why?
|
| Transcriptome | 1 | 2019 | 214 | 0.140 |
Why?
|
| Procainamide | 1 | 1997 | 9 | 0.140 |
Why?
|
| Fetal Growth Retardation | 2 | 2015 | 32 | 0.140 |
Why?
|
| Inflammation Mediators | 4 | 2017 | 166 | 0.130 |
Why?
|
| Health Status Disparities | 1 | 2017 | 65 | 0.130 |
Why?
|
| Th17 Cells | 1 | 2017 | 33 | 0.130 |
Why?
|
| Immunoassay | 2 | 2011 | 36 | 0.130 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2020 | 301 | 0.130 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2013 | 834 | 0.130 |
Why?
|
| Oklahoma | 3 | 2020 | 1038 | 0.130 |
Why?
|
| Heart Diseases | 1 | 1997 | 71 | 0.130 |
Why?
|
| Retrospective Studies | 7 | 2021 | 2612 | 0.130 |
Why?
|
| Anti-Arrhythmia Agents | 1 | 1997 | 117 | 0.130 |
Why?
|
| Transcription, Genetic | 2 | 2019 | 404 | 0.130 |
Why?
|
| Recurrence | 2 | 2015 | 325 | 0.130 |
Why?
|
| Healthy Volunteers | 1 | 2016 | 50 | 0.130 |
Why?
|
| Chromosomes, Human, X | 2 | 2016 | 38 | 0.130 |
Why?
|
| Liver Cirrhosis, Biliary | 1 | 2016 | 10 | 0.120 |
Why?
|
| Sex Chromosome Disorders of Sex Development | 1 | 2016 | 11 | 0.120 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 2016 | 34 | 0.120 |
Why?
|
| Leukocytes | 1 | 2016 | 72 | 0.120 |
Why?
|
| Nicotinamide-Nucleotide Adenylyltransferase | 1 | 2016 | 4 | 0.120 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 22 | 2 | 2013 | 14 | 0.120 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 1 | 2015 | 9 | 0.120 |
Why?
|
| North America | 4 | 2019 | 41 | 0.120 |
Why?
|
| Pregnancy Proteins | 1 | 2015 | 9 | 0.120 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2016 | 82 | 0.120 |
Why?
|
| Mood Disorders | 1 | 2015 | 25 | 0.120 |
Why?
|
| Leptin | 1 | 2015 | 67 | 0.120 |
Why?
|
| Epistasis, Genetic | 2 | 2012 | 24 | 0.120 |
Why?
|
| Interleukin-6 | 1 | 2016 | 194 | 0.110 |
Why?
|
| CD3 Complex | 1 | 2015 | 23 | 0.110 |
Why?
|
| Phosphoproteins | 2 | 2016 | 120 | 0.110 |
Why?
|
| Age Factors | 4 | 2019 | 734 | 0.110 |
Why?
|
| Ribosomes | 1 | 2015 | 32 | 0.110 |
Why?
|
| Precursor Cells, B-Lymphoid | 1 | 2014 | 12 | 0.110 |
Why?
|
| Receptors, Interleukin-6 | 1 | 2014 | 11 | 0.110 |
Why?
|
| Receptors, Complement 3d | 1 | 2014 | 7 | 0.110 |
Why?
|
| beta Karyopherins | 1 | 2014 | 13 | 0.110 |
Why?
|
| Interleukin-2 | 2 | 2011 | 35 | 0.110 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type I | 1 | 2014 | 2 | 0.110 |
Why?
|
| Capillaries | 2 | 2012 | 33 | 0.110 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type II | 1 | 2014 | 5 | 0.110 |
Why?
|
| Epidemiologic Methods | 2 | 2011 | 21 | 0.110 |
Why?
|
| ADAM Proteins | 1 | 2015 | 103 | 0.110 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2014 | 59 | 0.110 |
Why?
|
| Diagnosis-Related Groups | 1 | 2014 | 10 | 0.110 |
Why?
|
| Integrins | 1 | 1994 | 29 | 0.110 |
Why?
|
| Interferon-gamma | 4 | 2019 | 107 | 0.110 |
Why?
|
| Macrophage-1 Antigen | 2 | 1991 | 9 | 0.110 |
Why?
|
| Carrier Proteins | 1 | 2016 | 252 | 0.110 |
Why?
|
| Phosphoric Monoester Hydrolases | 1 | 1994 | 48 | 0.110 |
Why?
|
| Protein Kinase C | 2 | 1991 | 74 | 0.110 |
Why?
|
| ets-Domain Protein Elk-1 | 1 | 2013 | 13 | 0.110 |
Why?
|
| Molecular Sequence Data | 5 | 2012 | 1056 | 0.100 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 2 | 2013 | 51 | 0.100 |
Why?
|
| Herpesvirus 3, Human | 1 | 2013 | 12 | 0.100 |
Why?
|
| Herpes Zoster Vaccine | 1 | 2013 | 10 | 0.100 |
Why?
|
| OX40 Ligand | 1 | 2013 | 16 | 0.100 |
Why?
|
| Chromosomes, Human, Pair 11 | 2 | 2010 | 34 | 0.100 |
Why?
|
| Herpes Zoster | 1 | 2013 | 20 | 0.100 |
Why?
|
| Statistics, Nonparametric | 2 | 2010 | 82 | 0.100 |
Why?
|
| Interleukin-10 | 1 | 2013 | 74 | 0.100 |
Why?
|
| Toll-Like Receptor 7 | 1 | 2013 | 20 | 0.100 |
Why?
|
| Antigens, Differentiation, B-Lymphocyte | 1 | 2013 | 12 | 0.100 |
Why?
|
| Macrophage Activation | 1 | 2013 | 32 | 0.100 |
Why?
|
| Indians, South American | 1 | 2012 | 12 | 0.100 |
Why?
|
| DEAD-box RNA Helicases | 1 | 2013 | 26 | 0.100 |
Why?
|
| Asia | 3 | 2019 | 20 | 0.100 |
Why?
|
| Rheumatoid Factor | 2 | 2009 | 28 | 0.100 |
Why?
|
| International Agencies | 1 | 2012 | 6 | 0.100 |
Why?
|
| Cartilage, Articular | 1 | 2013 | 44 | 0.100 |
Why?
|
| Sjogren's Syndrome | 1 | 2016 | 274 | 0.100 |
Why?
|
| Cardiovascular Diseases | 2 | 2014 | 373 | 0.100 |
Why?
|
| Receptors, Immunologic | 1 | 2013 | 72 | 0.100 |
Why?
|
| Complement C1q | 2 | 2009 | 13 | 0.090 |
Why?
|
| Egg Proteins | 1 | 2012 | 17 | 0.090 |
Why?
|
| Disease Models, Animal | 3 | 2009 | 1494 | 0.090 |
Why?
|
| Ubiquitin-Conjugating Enzymes | 1 | 2012 | 15 | 0.090 |
Why?
|
| TNF Receptor-Associated Factor 6 | 1 | 2012 | 6 | 0.090 |
Why?
|
| Skin Diseases | 2 | 2009 | 30 | 0.090 |
Why?
|
| Genome, Human | 2 | 2013 | 70 | 0.090 |
Why?
|
| Purpura, Thrombotic Thrombocytopenic | 1 | 2015 | 216 | 0.090 |
Why?
|
| Molecular Motor Proteins | 1 | 2011 | 13 | 0.090 |
Why?
|
| Nervous System Diseases | 2 | 2009 | 40 | 0.090 |
Why?
|
| Stem Cell Transplantation | 1 | 2012 | 18 | 0.090 |
Why?
|
| Epilepsy | 1 | 2012 | 37 | 0.090 |
Why?
|
| Intracranial Thrombosis | 1 | 2011 | 2 | 0.090 |
Why?
|
| Myosin Heavy Chains | 1 | 2011 | 24 | 0.090 |
Why?
|
| Gastrointestinal Diseases | 2 | 2009 | 55 | 0.090 |
Why?
|
| Cell Adhesion Molecules | 1 | 2012 | 69 | 0.090 |
Why?
|
| Protein Phosphatase 2 | 1 | 2011 | 11 | 0.090 |
Why?
|
| Self Report | 1 | 2012 | 121 | 0.090 |
Why?
|
| Global Health | 3 | 2021 | 54 | 0.090 |
Why?
|
| Chromosomes, Human, Pair 4 | 1 | 2011 | 16 | 0.090 |
Why?
|
| Complement Factor H | 1 | 2011 | 14 | 0.090 |
Why?
|
| Microcirculation | 1 | 2012 | 113 | 0.090 |
Why?
|
| CD18 Antigens | 4 | 1997 | 14 | 0.090 |
Why?
|
| Exodeoxyribonucleases | 1 | 2011 | 6 | 0.090 |
Why?
|
| Indians, North American | 2 | 2012 | 534 | 0.090 |
Why?
|
| Base Sequence | 4 | 2012 | 588 | 0.090 |
Why?
|
| Apoptosis | 4 | 2013 | 777 | 0.090 |
Why?
|
| Pyruvate Dehydrogenase Complex | 1 | 2010 | 19 | 0.090 |
Why?
|
| Biological Products | 1 | 2012 | 66 | 0.090 |
Why?
|
| Nerve Tissue Proteins | 2 | 2012 | 154 | 0.090 |
Why?
|
| Intention to Treat Analysis | 1 | 2010 | 13 | 0.090 |
Why?
|
| Hyaluronan Receptors | 1 | 2010 | 31 | 0.090 |
Why?
|
| Antigens, Neoplasm | 1 | 2011 | 56 | 0.090 |
Why?
|
| Skin | 1 | 2012 | 151 | 0.080 |
Why?
|
| Mice | 6 | 2014 | 4732 | 0.080 |
Why?
|
| Introns | 3 | 2018 | 43 | 0.080 |
Why?
|
| Minority Groups | 2 | 2022 | 75 | 0.080 |
Why?
|
| Genetic Markers | 4 | 2012 | 92 | 0.080 |
Why?
|
| Synovitis | 1 | 2009 | 6 | 0.080 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2010 | 67 | 0.080 |
Why?
|
| Interleukin-21 Receptor alpha Subunit | 1 | 2009 | 4 | 0.080 |
Why?
|
| Flow Cytometry | 3 | 2016 | 291 | 0.080 |
Why?
|
| Cholestanetriol 26-Monooxygenase | 1 | 2009 | 2 | 0.080 |
Why?
|
| Musculoskeletal Diseases | 1 | 2009 | 5 | 0.080 |
Why?
|
| Allergy and Immunology | 1 | 2009 | 5 | 0.080 |
Why?
|
| Child | 5 | 2019 | 2271 | 0.080 |
Why?
|
| Kallikreins | 1 | 2009 | 4 | 0.080 |
Why?
|
| Kidney Cortex | 1 | 2009 | 5 | 0.080 |
Why?
|
| CD36 Antigens | 1 | 2009 | 8 | 0.080 |
Why?
|
| Protein Binding | 4 | 2013 | 664 | 0.070 |
Why?
|
| Blood Coagulation Disorders | 1 | 2009 | 28 | 0.070 |
Why?
|
| Fetal Death | 2 | 2015 | 21 | 0.070 |
Why?
|
| Nephrology | 1 | 2008 | 5 | 0.070 |
Why?
|
| Biomarkers, Tumor | 1 | 2011 | 409 | 0.070 |
Why?
|
| Lipoproteins, LDL | 2 | 2009 | 36 | 0.070 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2009 | 253 | 0.070 |
Why?
|
| Cholesterol | 1 | 2009 | 202 | 0.070 |
Why?
|
| Epigenomics | 2 | 2022 | 28 | 0.070 |
Why?
|
| Cells, Cultured | 3 | 2009 | 1009 | 0.070 |
Why?
|
| Regression Analysis | 3 | 2015 | 210 | 0.070 |
Why?
|
| Blotting, Western | 2 | 2002 | 515 | 0.070 |
Why?
|
| Models, Statistical | 2 | 2020 | 128 | 0.070 |
Why?
|
| Up-Regulation | 2 | 2021 | 247 | 0.070 |
Why?
|
| Phosphorylation | 5 | 2000 | 581 | 0.070 |
Why?
|
| Bayes Theorem | 3 | 2014 | 100 | 0.060 |
Why?
|
| Antibodies, Anti-Idiotypic | 3 | 2012 | 16 | 0.060 |
Why?
|
| Seroepidemiologic Studies | 1 | 2006 | 10 | 0.060 |
Why?
|
| Nausea | 2 | 2016 | 17 | 0.060 |
Why?
|
| Endothelial Cells | 1 | 2009 | 361 | 0.060 |
Why?
|
| Joints | 2 | 2018 | 12 | 0.060 |
Why?
|
| Anemia, Hemolytic | 1 | 2006 | 22 | 0.060 |
Why?
|
| Mycophenolic Acid | 1 | 2005 | 18 | 0.060 |
Why?
|
| Multiple Organ Failure | 1 | 2006 | 31 | 0.060 |
Why?
|
| Morbidity | 2 | 2018 | 58 | 0.060 |
Why?
|
| Immunophenotyping | 2 | 2016 | 61 | 0.060 |
Why?
|
| Prothrombin | 2 | 2008 | 15 | 0.060 |
Why?
|
| Cyclophosphamide | 1 | 2005 | 41 | 0.060 |
Why?
|
| Core Binding Factor Alpha 3 Subunit | 2 | 2018 | 7 | 0.060 |
Why?
|
| Symptom Assessment | 2 | 2017 | 15 | 0.060 |
Why?
|
| Linear Models | 2 | 2019 | 202 | 0.060 |
Why?
|
| Drug Industry | 1 | 2005 | 14 | 0.060 |
Why?
|
| Estrogen Replacement Therapy | 1 | 2005 | 43 | 0.060 |
Why?
|
| Observer Variation | 3 | 2010 | 43 | 0.060 |
Why?
|
| Postmenopause | 1 | 2005 | 84 | 0.060 |
Why?
|
| Community Networks | 1 | 2004 | 10 | 0.060 |
Why?
|
| Inflammation | 2 | 2013 | 641 | 0.060 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2004 | 58 | 0.060 |
Why?
|
| Physical Examination | 1 | 2004 | 53 | 0.050 |
Why?
|
| Tetradecanoylphorbol Acetate | 3 | 1994 | 31 | 0.050 |
Why?
|
| Models, Genetic | 2 | 2018 | 125 | 0.050 |
Why?
|
| Real-Time Polymerase Chain Reaction | 2 | 2016 | 133 | 0.050 |
Why?
|
| Phosphatidylserines | 1 | 2004 | 20 | 0.050 |
Why?
|
| Age of Onset | 2 | 2017 | 72 | 0.050 |
Why?
|
| HEK293 Cells | 2 | 2016 | 188 | 0.050 |
Why?
|
| Pain Measurement | 1 | 2004 | 172 | 0.050 |
Why?
|
| Arterial Occlusive Diseases | 1 | 2004 | 44 | 0.050 |
Why?
|
| Epitopes | 2 | 2001 | 185 | 0.050 |
Why?
|
| Amino Acid Sequence | 2 | 1995 | 695 | 0.050 |
Why?
|
| Pedigree | 2 | 2016 | 155 | 0.050 |
Why?
|
| Apolipoprotein L1 | 2 | 2014 | 10 | 0.050 |
Why?
|
| Androgens | 1 | 2003 | 47 | 0.050 |
Why?
|
| Peptide Library | 1 | 2003 | 26 | 0.050 |
Why?
|
| Molecular Mimicry | 1 | 2003 | 30 | 0.050 |
Why?
|
| Societies, Medical | 2 | 2014 | 93 | 0.050 |
Why?
|
| Cell Aggregation | 2 | 1994 | 3 | 0.050 |
Why?
|
| N-Formylmethionine Leucyl-Phenylalanine | 2 | 1994 | 10 | 0.050 |
Why?
|
| NF-kappa B | 2 | 2013 | 191 | 0.050 |
Why?
|
| Alprostadil | 1 | 2022 | 4 | 0.050 |
Why?
|
| Oligopeptides | 1 | 2003 | 97 | 0.050 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2019 | 164 | 0.050 |
Why?
|
| Clinical Studies as Topic | 1 | 2022 | 1 | 0.050 |
Why?
|
| Area Under Curve | 2 | 2015 | 95 | 0.050 |
Why?
|
| Intercellular Adhesion Molecule-1 | 2 | 2012 | 58 | 0.050 |
Why?
|
| Cultural Diversity | 1 | 2022 | 19 | 0.050 |
Why?
|
| Cross Reactions | 1 | 2002 | 74 | 0.050 |
Why?
|
| Algorithms | 2 | 2018 | 430 | 0.050 |
Why?
|
| Endothelium | 1 | 2001 | 28 | 0.040 |
Why?
|
| Antimalarials | 1 | 2021 | 25 | 0.040 |
Why?
|
| Lipid Metabolism | 1 | 2002 | 134 | 0.040 |
Why?
|
| Thromboplastin | 1 | 2021 | 28 | 0.040 |
Why?
|
| Phospholipids | 1 | 2001 | 76 | 0.040 |
Why?
|
| Prenatal Care | 1 | 2001 | 41 | 0.040 |
Why?
|
| Hemostasis | 1 | 2001 | 48 | 0.040 |
Why?
|
| Alkaloids | 2 | 1991 | 16 | 0.040 |
Why?
|
| Mice, Knockout | 2 | 2014 | 861 | 0.040 |
Why?
|
| Models, Economic | 1 | 2020 | 8 | 0.040 |
Why?
|
| Rheumatic Diseases | 1 | 2021 | 33 | 0.040 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2013 | 140 | 0.040 |
Why?
|
| Endothelial Protein C Receptor | 2 | 2012 | 7 | 0.040 |
Why?
|
| 3' Untranslated Regions | 2 | 2013 | 34 | 0.040 |
Why?
|
| Peru | 1 | 2020 | 31 | 0.040 |
Why?
|
| Hospitalization | 1 | 2022 | 199 | 0.040 |
Why?
|
| Cost-Benefit Analysis | 1 | 2020 | 114 | 0.040 |
Why?
|
| Altruism | 1 | 2020 | 8 | 0.040 |
Why?
|
| Risk | 1 | 2020 | 137 | 0.040 |
Why?
|
| Thrombocytopenia | 1 | 2001 | 113 | 0.040 |
Why?
|
| Culture | 1 | 2020 | 27 | 0.040 |
Why?
|
| Multilevel Analysis | 1 | 2020 | 8 | 0.040 |
Why?
|
| Mononeuropathies | 1 | 2019 | 1 | 0.040 |
Why?
|
| Genetics, Population | 2 | 2012 | 72 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 1 | 2 | 2011 | 27 | 0.040 |
Why?
|
| Heparin | 2 | 2015 | 111 | 0.040 |
Why?
|
| Focus Groups | 1 | 2020 | 101 | 0.040 |
Why?
|
| Kidney Diseases | 2 | 2011 | 61 | 0.040 |
Why?
|
| Contraindications, Drug | 1 | 2019 | 1 | 0.040 |
Why?
|
| Migraine with Aura | 1 | 2019 | 2 | 0.040 |
Why?
|
| Perception | 1 | 2020 | 90 | 0.040 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2019 | 18 | 0.040 |
Why?
|
| Drug Utilization | 1 | 2019 | 28 | 0.040 |
Why?
|
| Embryo Implantation | 1 | 2019 | 6 | 0.040 |
Why?
|
| Blood Platelets | 1 | 2001 | 206 | 0.040 |
Why?
|
| Patient Outcome Assessment | 1 | 2019 | 14 | 0.040 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 1 | 2019 | 15 | 0.040 |
Why?
|
| Antibody Formation | 2 | 2014 | 77 | 0.040 |
Why?
|
| Educational Status | 1 | 2019 | 112 | 0.040 |
Why?
|
| Enhancer of Zeste Homolog 2 Protein | 1 | 2018 | 14 | 0.040 |
Why?
|
| Treponema denticola | 1 | 2018 | 6 | 0.040 |
Why?
|
| Porphyromonas gingivalis | 1 | 2018 | 7 | 0.040 |
Why?
|
| Reference Values | 1 | 2019 | 199 | 0.040 |
Why?
|
| Mitosis | 1 | 2019 | 115 | 0.040 |
Why?
|
| Lung | 1 | 2021 | 380 | 0.040 |
Why?
|
| Complement Factor B | 1 | 2018 | 3 | 0.040 |
Why?
|
| Injection Site Reaction | 1 | 2017 | 2 | 0.040 |
Why?
|
| Infant, Newborn | 1 | 2001 | 899 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 16 | 2 | 2008 | 20 | 0.040 |
Why?
|
| United States Virgin Islands | 1 | 2017 | 4 | 0.030 |
Why?
|
| British Virgin Islands | 1 | 2017 | 4 | 0.030 |
Why?
|
| Puerto Rico | 1 | 2017 | 6 | 0.030 |
Why?
|
| Drug Tolerance | 1 | 2017 | 37 | 0.030 |
Why?
|
| Complement Membrane Attack Complex | 1 | 2018 | 16 | 0.030 |
Why?
|
| Confidence Intervals | 2 | 2008 | 68 | 0.030 |
Why?
|
| Multifactorial Inheritance | 1 | 2017 | 13 | 0.030 |
Why?
|
| Binding Sites | 1 | 2018 | 354 | 0.030 |
Why?
|
| Mutagenesis, Insertional | 1 | 2017 | 38 | 0.030 |
Why?
|
| Smoking | 1 | 2021 | 476 | 0.030 |
Why?
|
| Sequence Deletion | 1 | 2017 | 66 | 0.030 |
Why?
|
| Medication Adherence | 1 | 2018 | 48 | 0.030 |
Why?
|
| Canada | 1 | 2017 | 60 | 0.030 |
Why?
|
| Creatinine | 1 | 2017 | 59 | 0.030 |
Why?
|
| Receptor, Interferon alpha-beta | 1 | 2017 | 7 | 0.030 |
Why?
|
| DNA Topoisomerases, Type I | 1 | 2016 | 7 | 0.030 |
Why?
|
| Stem Cell Factor | 1 | 2016 | 5 | 0.030 |
Why?
|
| Interleukin-12 Subunit p40 | 1 | 2016 | 8 | 0.030 |
Why?
|
| Centromere Protein B | 1 | 2016 | 3 | 0.030 |
Why?
|
| Interleukin 1 Receptor Antagonist Protein | 1 | 2016 | 10 | 0.030 |
Why?
|
| Ligands | 2 | 2010 | 178 | 0.030 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2016 | 18 | 0.030 |
Why?
|
| Plasma Cells | 1 | 2016 | 21 | 0.030 |
Why?
|
| Models, Biological | 1 | 2019 | 468 | 0.030 |
Why?
|
| Military Personnel | 2 | 2007 | 49 | 0.030 |
Why?
|
| Cell Differentiation | 1 | 2019 | 419 | 0.030 |
Why?
|
| Interferon-beta | 1 | 2016 | 40 | 0.030 |
Why?
|
| Hypertension | 1 | 2019 | 309 | 0.030 |
Why?
|
| Interleukin-17 | 1 | 2016 | 52 | 0.030 |
Why?
|
| Diarrhea | 1 | 2016 | 56 | 0.030 |
Why?
|
| Gene Dosage | 1 | 2016 | 35 | 0.030 |
Why?
|
| Sex Chromosome Aberrations | 1 | 2016 | 16 | 0.030 |
Why?
|
| Trisomy | 1 | 2016 | 19 | 0.030 |
Why?
|
| Brazil | 1 | 2016 | 24 | 0.030 |
Why?
|
| Oxidoreductases Acting on CH-CH Group Donors | 1 | 2016 | 10 | 0.030 |
Why?
|
| Sex Distribution | 1 | 2016 | 78 | 0.030 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2016 | 75 | 0.030 |
Why?
|
| STAT3 Transcription Factor | 1 | 2016 | 97 | 0.030 |
Why?
|
| Genotyping Techniques | 1 | 2016 | 21 | 0.030 |
Why?
|
| Neuropsychological Tests | 2 | 2008 | 247 | 0.030 |
Why?
|
| Cytoskeletal Proteins | 1 | 2016 | 42 | 0.030 |
Why?
|
| Antigens | 1 | 2016 | 68 | 0.030 |
Why?
|
| Sarcoidosis | 1 | 2016 | 38 | 0.030 |
Why?
|
| Endoglin | 1 | 2015 | 2 | 0.030 |
Why?
|
| Placenta Growth Factor | 1 | 2015 | 6 | 0.030 |
Why?
|
| Pregnancy, High-Risk | 1 | 2015 | 6 | 0.030 |
Why?
|
| Pregnancy Trimester, Second | 1 | 2015 | 18 | 0.030 |
Why?
|
| DNA, Complementary | 1 | 1995 | 78 | 0.030 |
Why?
|
| Metabolic Clearance Rate | 1 | 2015 | 18 | 0.030 |
Why?
|
| Sepsis | 1 | 2016 | 86 | 0.030 |
Why?
|
| Dizziness | 1 | 2015 | 10 | 0.030 |
Why?
|
| Infant Mortality | 1 | 2015 | 15 | 0.030 |
Why?
|
| Obstetric Labor Complications | 1 | 2015 | 18 | 0.030 |
Why?
|
| Ribonucleoproteins | 1 | 2016 | 154 | 0.030 |
Why?
|
| Interferon Regulatory Factor-7 | 1 | 2015 | 7 | 0.030 |
Why?
|
| Dual-Specificity Phosphatases | 1 | 2015 | 6 | 0.030 |
Why?
|
| Pulmonary Embolism | 1 | 2016 | 126 | 0.030 |
Why?
|
| Gestational Age | 1 | 2015 | 146 | 0.030 |
Why?
|
| Mice, SCID | 1 | 2014 | 60 | 0.030 |
Why?
|
| Mice, Inbred NOD | 1 | 2014 | 50 | 0.030 |
Why?
|
| Immunoglobulins | 1 | 2014 | 34 | 0.030 |
Why?
|
| Antigens, Surface | 1 | 2014 | 39 | 0.030 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2015 | 97 | 0.030 |
Why?
|
| Receptors, Complement 3b | 1 | 2014 | 7 | 0.030 |
Why?
|
| Killer Cells, Natural | 1 | 2015 | 64 | 0.030 |
Why?
|
| Fas Ligand Protein | 1 | 2014 | 7 | 0.030 |
Why?
|
| fas Receptor | 1 | 2014 | 19 | 0.030 |
Why?
|
| ADAMTS13 Protein | 1 | 2015 | 126 | 0.030 |
Why?
|
| Ethers, Cyclic | 1 | 1994 | 1 | 0.030 |
Why?
|
| Okadaic Acid | 1 | 1994 | 5 | 0.030 |
Why?
|
| Survival Rate | 1 | 2015 | 431 | 0.030 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 1994 | 19 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 8 | 1 | 2014 | 14 | 0.030 |
Why?
|
| Receptors, Leukocyte-Adhesion | 2 | 1991 | 2 | 0.030 |
Why?
|
| Infant, Premature | 1 | 2015 | 144 | 0.030 |
Why?
|
| Staurosporine | 2 | 1991 | 10 | 0.030 |
Why?
|
| Electrophoretic Mobility Shift Assay | 1 | 2014 | 50 | 0.030 |
Why?
|
| Macromolecular Substances | 1 | 1994 | 53 | 0.030 |
Why?
|
| Cluster Headache | 1 | 2013 | 1 | 0.030 |
Why?
|
| Tension-Type Headache | 1 | 2013 | 6 | 0.030 |
Why?
|
| Intracranial Hypertension | 1 | 2013 | 6 | 0.030 |
Why?
|
| Administration, Oral | 2 | 2005 | 190 | 0.030 |
Why?
|
| Proteins | 1 | 2016 | 253 | 0.030 |
Why?
|
| Migraine Disorders | 1 | 2013 | 22 | 0.030 |
Why?
|
| Immunocompromised Host | 1 | 2013 | 28 | 0.030 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2013 | 114 | 0.030 |
Why?
|
| NADH Dehydrogenase | 1 | 2013 | 6 | 0.030 |
Why?
|
| Nitric Oxide Synthase Type I | 1 | 2013 | 15 | 0.030 |
Why?
|
| Drug Substitution | 1 | 2013 | 5 | 0.030 |
Why?
|
| Electron Transport Complex I | 1 | 2013 | 13 | 0.030 |
Why?
|
| Guideline Adherence | 1 | 2014 | 95 | 0.030 |
Why?
|
| Glutathione Reductase | 1 | 2013 | 22 | 0.030 |
Why?
|
| Autoantigens | 2 | 2008 | 212 | 0.030 |
Why?
|
| Ku Autoantigen | 1 | 2013 | 12 | 0.030 |
Why?
|
| Interferon-Induced Helicase, IFIH1 | 1 | 2013 | 11 | 0.030 |
Why?
|
| Antigens, Nuclear | 1 | 2013 | 22 | 0.020 |
Why?
|
| Methotrexate | 1 | 2013 | 36 | 0.020 |
Why?
|
| Hand | 1 | 2013 | 26 | 0.020 |
Why?
|
| Kinetics | 1 | 1994 | 551 | 0.020 |
Why?
|
| Gene Regulatory Networks | 1 | 2013 | 78 | 0.020 |
Why?
|
| Cell Line, Transformed | 1 | 2012 | 42 | 0.020 |
Why?
|
| Lymphocytes | 1 | 2013 | 90 | 0.020 |
Why?
|
| Cell Survival | 1 | 1994 | 416 | 0.020 |
Why?
|
| Feedback | 1 | 2012 | 33 | 0.020 |
Why?
|
| Platelet Endothelial Cell Adhesion Molecule-1 | 1 | 2012 | 13 | 0.020 |
Why?
|
| Serositis | 1 | 2011 | 2 | 0.020 |
Why?
|
| Blood Sedimentation | 1 | 2011 | 5 | 0.020 |
Why?
|
| Lymphopenia | 1 | 2011 | 8 | 0.020 |
Why?
|
| Adiponectin | 1 | 2012 | 29 | 0.020 |
Why?
|
| Infant | 1 | 2015 | 1019 | 0.020 |
Why?
|
| Exanthema | 1 | 2011 | 14 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2013 | 458 | 0.020 |
Why?
|
| Neoplasm Proteins | 1 | 2012 | 123 | 0.020 |
Why?
|
| Immunity, Humoral | 1 | 2011 | 47 | 0.020 |
Why?
|
| Oral Ulcer | 1 | 2011 | 6 | 0.020 |
Why?
|
| Cost of Illness | 1 | 2012 | 54 | 0.020 |
Why?
|
| Complement C3b | 1 | 1991 | 4 | 0.020 |
Why?
|
| Cytosine | 1 | 2011 | 6 | 0.020 |
Why?
|
| GPI-Linked Proteins | 1 | 2011 | 13 | 0.020 |
Why?
|
| Lymphocyte Depletion | 1 | 2011 | 8 | 0.020 |
Why?
|
| Schools, Public Health | 1 | 2011 | 3 | 0.020 |
Why?
|
| Tumor Necrosis Factor alpha-Induced Protein 3 | 1 | 2011 | 24 | 0.020 |
Why?
|
| History, 21st Century | 1 | 2011 | 49 | 0.020 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2011 | 54 | 0.020 |
Why?
|
| Delphi Technique | 1 | 2010 | 23 | 0.020 |
Why?
|
| Cell Degranulation | 1 | 1990 | 5 | 0.020 |
Why?
|
| Diglycerides | 1 | 1990 | 10 | 0.020 |
Why?
|
| Receptor, Platelet-Derived Growth Factor alpha | 1 | 2011 | 31 | 0.020 |
Why?
|
| History, 20th Century | 1 | 2011 | 84 | 0.020 |
Why?
|
| Gene Deletion | 1 | 2011 | 120 | 0.020 |
Why?
|
| Phagocytosis | 1 | 1991 | 80 | 0.020 |
Why?
|
| Skin Physiological Phenomena | 1 | 2010 | 8 | 0.020 |
Why?
|
| Sequence Analysis, DNA | 1 | 2012 | 376 | 0.020 |
Why?
|
| c-Mer Tyrosine Kinase | 1 | 2010 | 13 | 0.020 |
Why?
|
| Acute Disease | 1 | 2010 | 155 | 0.020 |
Why?
|
| In Vitro Techniques | 1 | 1990 | 242 | 0.020 |
Why?
|
| Influenza, Human | 1 | 2011 | 92 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2010 | 145 | 0.020 |
Why?
|
| Enzyme Activation | 1 | 1990 | 267 | 0.020 |
Why?
|
| Membrane Glycoproteins | 1 | 2011 | 147 | 0.020 |
Why?
|
| Macrophages | 1 | 2013 | 302 | 0.020 |
Why?
|
| Vaccination | 1 | 2011 | 192 | 0.020 |
Why?
|
| Molecular Targeted Therapy | 1 | 2011 | 137 | 0.020 |
Why?
|
| Foam Cells | 1 | 2009 | 8 | 0.020 |
Why?
|
| Receptors, Interferon | 1 | 2009 | 13 | 0.020 |
Why?
|
| Glomerular Basement Membrane | 1 | 2009 | 3 | 0.020 |
Why?
|
| Mice, Inbred DBA | 1 | 2009 | 30 | 0.020 |
Why?
|
| Sequence Homology, Nucleic Acid | 1 | 2009 | 48 | 0.020 |
Why?
|
| Korea | 1 | 2009 | 7 | 0.020 |
Why?
|
| Colombia | 1 | 2009 | 9 | 0.020 |
Why?
|
| Japan | 1 | 2009 | 23 | 0.020 |
Why?
|
| Meta-Analysis as Topic | 1 | 2009 | 32 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2009 | 200 | 0.020 |
Why?
|
| United Kingdom | 1 | 2009 | 77 | 0.020 |
Why?
|
| Species Specificity | 1 | 2009 | 193 | 0.020 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2009 | 94 | 0.020 |
Why?
|
| Mexico | 1 | 2009 | 91 | 0.020 |
Why?
|
| Demography | 1 | 2009 | 93 | 0.020 |
Why?
|
| Cell Line | 2 | 2009 | 698 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2009 | 194 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 1 | 2009 | 278 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2013 | 1601 | 0.020 |
Why?
|
| Abortion, Habitual | 1 | 2008 | 4 | 0.020 |
Why?
|
| Receptors, Glutamate | 1 | 2008 | 3 | 0.020 |
Why?
|
| Bone Diseases | 1 | 2008 | 11 | 0.020 |
Why?
|
| Thrombophilia | 1 | 2008 | 10 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 3 | 1 | 2008 | 17 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 6 | 1 | 2008 | 19 | 0.020 |
Why?
|
| Exons | 1 | 2008 | 42 | 0.020 |
Why?
|
| Probability | 1 | 2008 | 78 | 0.020 |
Why?
|
| ROC Curve | 1 | 2008 | 144 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2009 | 509 | 0.020 |
Why?
|
| Mutation | 1 | 2011 | 864 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2009 | 453 | 0.020 |
Why?
|
| Ethinyl Estradiol | 1 | 2005 | 2 | 0.020 |
Why?
|
| Norethindrone | 1 | 2005 | 2 | 0.020 |
Why?
|
| Infusions, Intravenous | 1 | 2005 | 102 | 0.010 |
Why?
|
| Medroxyprogesterone | 1 | 2005 | 4 | 0.010 |
Why?
|
| Estrogens, Conjugated (USP) | 1 | 2005 | 15 | 0.010 |
Why?
|
| Cross-Over Studies | 1 | 2005 | 137 | 0.010 |
Why?
|
| Sickness Impact Profile | 1 | 2004 | 4 | 0.010 |
Why?
|
| Ambulatory Care Facilities | 1 | 2004 | 54 | 0.010 |
Why?
|
| Abortion, Spontaneous | 1 | 2004 | 17 | 0.010 |
Why?
|
| Pregnancy Complications, Hematologic | 1 | 2003 | 38 | 0.010 |
Why?
|
| Cardiolipins | 1 | 2003 | 12 | 0.010 |
Why?
|
| Peptide Biosynthesis | 1 | 2003 | 3 | 0.010 |
Why?
|
| Safety | 1 | 2002 | 32 | 0.010 |
Why?
|
| Prednisolone | 1 | 2002 | 6 | 0.010 |
Why?
|
| Peptide Fragments | 1 | 2003 | 202 | 0.010 |
Why?
|
| Serine-Arginine Splicing Factors | 1 | 2000 | 5 | 0.010 |
Why?
|
| RNA-Binding Proteins | 1 | 2000 | 87 | 0.010 |
Why?
|
| HeLa Cells | 1 | 2000 | 208 | 0.010 |
Why?
|
| Polymorphism, Restriction Fragment Length | 1 | 1999 | 26 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2000 | 465 | 0.010 |
Why?
|
| Photometry | 1 | 1979 | 3 | 0.010 |
Why?
|
| Cytological Techniques | 1 | 1979 | 6 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 1999 | 270 | 0.010 |
Why?
|
| Chromosomes, Human | 1 | 1979 | 33 | 0.010 |
Why?
|
| Chromosomes | 1 | 1979 | 59 | 0.010 |
Why?
|
| Proteolipids | 1 | 1998 | 4 | 0.010 |
Why?
|
| Binding Sites, Antibody | 1 | 1998 | 14 | 0.010 |
Why?
|
| Subcellular Fractions | 1 | 1997 | 22 | 0.010 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 1997 | 169 | 0.010 |
Why?
|
| Cell Membrane | 1 | 1997 | 259 | 0.010 |
Why?
|
| Glucans | 1 | 1991 | 6 | 0.010 |
Why?
|
| Receptors, Fc | 1 | 1991 | 31 | 0.010 |
Why?
|
| Deer | 1 | 1979 | 6 | 0.000 |
Why?
|
| Computers | 1 | 1979 | 30 | 0.000 |
Why?
|
| Cricetulus | 1 | 1979 | 56 | 0.000 |
Why?
|
| Cricetinae | 1 | 1979 | 131 | 0.000 |
Why?
|
| Centromere | 1 | 1979 | 41 | 0.000 |
Why?
|